Program
luxdegalutamide
A development code. Also written as “JSB462”.
In Novartis's pipeline, Androgen receptor protein degrader
. Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by Novartis.
Furthest: phase 2, since May 8, 20253 company-led studies, 3 open or runningNext primary completion: Dec 3, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 33 open or running | phase 2since May 8, 2025 | May 8, 2025 | Dec 3, 2026phase 2 · NCT06991556 |
- Named in Novartis’s own pipeline as
JSB462 (luxdegalutamide)
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 8, 2025First studies: 2 phase 2 studiesFirst studyNCT06991556, NCT07047118
- Sep 8, 2025Phase 1 study in Prostatic NeoplasmsNCT07174063 · 6 enrolled · Japan
Ahead
- Dec 3, 2026Primary completion: phase 2 study in Metastatic Hormone-sensitive Prostate CancerNCT06991556
- Jan 29, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07174063
- Jul 16, 2027Primary completion: phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT07047118
TargetBeta
“Androgen receptor protein degrader”the company's pipeline, read by Claude · source
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07174063Prostatic Neoplasms · Japan | 1 | Active, not recruiting | Jan 29, 2027 | 6 |
| NCT07047118Prostatic Neoplasms, Castration-Resistant · United States, Australia, Austria and more | 2 | Active, not recruiting | Jul 16, 2027 | 138 |
| NCT06991556Metastatic Hormone-sensitive Prostate Cancer · United States, Australia, Brazil and more | 2 | Active, not recruiting | Dec 3, 2026 | 168 |
How it is read
Names in the registry
- “JSB462”, 3 entries
Codes read as this program: JSB462.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
- Prostatic Neoplasms, Castration-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.